- All adult patients with relapsed or refractory AML, as well as younger de novo AML
patients are eligible for the study
- Relapsed, refractory, and de novo AML patients are allowed in Phase I of this study
- Phase II will only allow enrollment of younger de novo AML
- AML following an antecedent hematologic disorder (myelodysplasia or
myeloproliferation) of greater than 2 months duration
- De novo patients with M3 AML
- AML secondary to exposure to chemotherapy or radiation